Study S000399

Role of Glucagon-like Peptide 1 Receptor Agonist (GLP1 RA) Dulaglutide on Cerebral Hemodynamics In Patients With Severe and symptomAtic steNosis of inTracranial Internal Carotid Artery or Middle Cerebral Artery With Impaired Cerebral Vasodilatory Reserve- an Open-label Randomised Clinical Trial (RADIANT)

ClinicalTrials.gov record

Registration

Registration: NCT07282041
Acronym: RADIANT
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2; PHASE3
Masking: SINGLE
Status: RECRUITING
Enrollment: 130
Start: 2025-12-17
Primary completion: 2030-12-01
Lead sponsor: National University of Singapore
Conditions: Intracranial Atherosclerosis; Stroke, Ischemic
Interventions: DRUG:Dulaglutide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

To evaluate whether GLP1 RA (Dulaglutide) therapy would improveme cerebral vasodilatory reserve by at least 4 points in patients with severe stenosis of ICA or MCA [within 1 year]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.